In Friday’s Wall Street session, SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares traded at $1.95, down -3.94% from the previous session.
SLS stock price is now 20.70% away from the 50-day moving average and 52.27% away from the 200-day moving average. The market capitalization of the company currently stands at $194.57M.
With the price target of $18, Cantor Fitzgerald recently initiated with Overweight rating for SELLAS Life Sciences Group Inc (NASDAQ: SLS). , while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, VAN NOSTRAND ROBERT L, Director bought 10,000 shares of the company’s stock on Jun 12 ’25. The stock was bought for $14,800 at an average price of $1.48. Upon completion of the transaction, the Director now directly owns 20,400 shares in the company, valued at $39780.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 30 ’25, Director Wasman Jane bought 20,000 shares of the business’s stock. A total of $33,800 was incurred on buying the stock at an average price of $1.69. This leaves the insider owning 30,400 shares of the company worth $59280.0. A total of 2.11% of the company’s stock is owned by insiders.
During the past 12 months, SELLAS Life Sciences Group Inc has had a low of $0.77 and a high of $2.12. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 4.64, and a quick ratio of 4.64. The fifty day moving average price for SLS is $1.6156 and a two-hundred day moving average price translates $1.2806 for the stock.
The latest earnings results from SELLAS Life Sciences Group Inc (NASDAQ: SLS) was released for 2025-03-31.
